Cell-based therapeutics are an emerging modality with the potential to treat many currently intractable diseases through uniquely powerful modes of action. Despite notable recent clinical and commercial successes, cell-based therapies continue to face numerous challenges that limit their widespread translation and commercialization, including identification of the appropriate cell source, generation of a sufficiently viable, potent and safe product that meets patient- and disease-specific needs, and the development of scalable manufacturing processes. These hurdles are being addressed through the use of cutting-edge basic research driven by next-generation engineering approaches, including genome and epigenome editing, synthetic biology and the use of biomaterials.

基于细胞的疗法是一种新兴的治疗方法，有可能通过独特的强大作用模式来治疗许多目前难以治疗的疾病。尽管最近在临床和商业上取得了显着的成功，但基于细胞的疗法仍然面临着限制其广泛转化和商业化的众多挑战，包括识别适当的细胞来源，产生足够可行、有效和安全的产品来满足患者和疾病的需要。特定需求以及可扩展制造工艺的开发。这些障碍正在通过使用由下一代工程方法驱动的尖端基础研究来解决，包括基因组和表观基因组编辑、合成生物学和生物材料的使用。